You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Optimal dosing regimen of CD73 blockade improves tumor response to radiotherapy through iCOS downregulation

Authors

  • Lydia Meziani Laboratory of Radiation Oncology, Department of Radiation Oncology, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, SwitzerlandINSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France PubMed articlesGoogle scholar articles
  • Marine Gerbé de Thoré INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France PubMed articlesGoogle scholar articles
  • Céline Clémenson INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France PubMed articlesGoogle scholar articles
  • Winchygn Liu INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France PubMed articlesGoogle scholar articles
  • Pierre-Antoine Laurent INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, FranceDepartment of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France PubMed articlesGoogle scholar articles
  • Michele Mondini INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France PubMed articlesGoogle scholar articles
  • Marie-Catherine Vozenin Laboratory of Radiation Oncology, Department of Radiation Oncology, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Eric Deutsch INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, FranceDepartment of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France PubMed articlesGoogle scholar articles

Citation

Meziani L, Gerbé de Thoré M, Clémenson C, et al
Optimal dosing regimen of CD73 blockade improves tumor response to radiotherapy through iCOS downregulation
Journal for ImmunoTherapy of Cancer 2023;11:e006846. doi: 10.1136/jitc-2023-006846
Online issue publication 
June 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.